Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20416634 | 1.00 | ADORA2A (0.50) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL20416583 | 0.89 | ADORA2A (0.51) | ADORA2AADORA2BADORA1 | |
| SCHEMBL30402081 | 0.89 | ADORA2A (0.51) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20417225 | 0.87 | ADORA2A (0.57) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL30401085 | 0.87 | ADORA2A (0.46) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL20401349 | 0.87 | ADORA2A (0.46) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL20436540 | 0.86 | ADORA2A (0.49) | ADORA2AADORA2BADORA1 | |
| SCHEMBL25383480 | 0.85 | ADORA2A (0.46) | ADORA2AADORA2BADORA1KLKB1 | |
| SCHEMBL20401358 | 0.85 | ADORA2A (0.54) | ADORA2AADORA2BADORA1 | |
| SCHEMBL30402231 | 0.85 | ADORA2A (0.47) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768859-A | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-110214012-B | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-05-09 | — | — | CN | disclosed |